PREMISE: Pandemic Response Repository through Microbial and Immune Surveillance and Epidemiology

前提：通过微生物和免疫监测及流行病学建立流行病应对知识库

• 批准号: 10686719
• 负责人: Daniel Cesar Douek
• 金额: $ 472.8万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10686719
• 关键词: Antigens; Biological Assay; Country; Data; Diagnostic; Early Diagnosis; Human; Immune response; Immunologic Epidemiology; Immunologic Surveillance; Immunology procedure; Laboratories; Monoclonal Antibodies; Population; Prevention therapy; Reagent; Serology; Therapeutic; Translating; Zoonoses; cohort; cross reactivity; data resource; detection assay; diagnostic assay; genetic analysis; human pathogen; microbial; novel virus; pandemic disease; pandemic preparedness; programs; prophylactic; repository; response; vaccine development; vaccine discovery

PREMISE is a proactive pandemic preparedness program to establish a stockpile of tangible immunobiological countermeasures to accelerate the response to pandemic threats globally PREMISE assesses immune responses against known and novel viruses in targeted human populations PREMISE translates these data into diagnostic, therapeutic and prophylactic assets Deliverables: Reagent and data resources for early detection and diagnostic assays Monoclonal antibodies with potential for prevention and therapy Immunogens suitable for vaccine discovery and development Activities: Conduct genetic analysis of zoonotic reservoirs and symptomatic humans for pathogen discovery Develop high throughput, multiplexed serologic and cellular immune assays Identify antigen-specic and cross-reactive immune responses to known and novel viruses in strategically targeted cohorts Establish and expand in-country laboratory assay capabilities

前提是一个积极主动的大流行准备计划，旨在建立有形免疫生物学对策的库存，以加快全球大流行威胁的反应 前提评估针对靶向人群中已知病毒和新型病毒的免疫反应 前提将这些数据转化为诊断，治疗和预防性资产 可交付成果： 试剂和数据资源用于早期检测和诊断测定 具有预防和治疗潜力的单克隆抗体 适用于疫苗发现和开发的免疫原子 活动： 进行人畜共患病和有症状的人类进行病原体的遗传分析 发展高通量，多重血清学和细胞免疫测定 在战略性靶向人群中确定对已知和新型病毒的抗原特异性和交叉反应性免疫反应 建立和扩展国内实验室测定能力